Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 67Genitourinary 21Thoracic 17Gynecologic 9CNS 9Gastrointestinal 5Other solid neoplasm 4Head & Neck 4Tumor-Agnostic 3Endocrine 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
sacituzumab govitecan × Tumor-Agnostic × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03964727 2026-04-28

TROPiCS-03

Gilead Sciences

Phase 2 Active not recruiting
227 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡